Taysha grants Astellas options for GAN/Rett programs; $20M upfront + $30M equity raise

Taysha Gene Therapies, Inc.

Astellas gets exclusive options to license TSHA-120 (GAN) and TSHA-102 (Rett) post specified clinical/regulatory milestones.
Upfront payment of $20M from Astellas; $30M private placement of 7.27M shares of common stock at ~$4.13/share.
TSHA-120 Type B end-of-Phase 2 FDA meeting scheduled Dec 13, 2022; update expected mid-Jan 2023.
TSHA-102 preliminary safety/efficacy data for adult cohort now expected H1 2023 (delayed from year-end 2022); female pediatric trial to start H1 2023.
Taysha agrees to change-of-control restrictions during Rett option period; Astellas receives board observer right.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Taysha Gene Therapies, Inc. entered into Option Agreement with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas") valued at $20.0 million (effective 2022-10-21).

Action: entry
Agreement: license
Counterparty: Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas")
Value: $20.0 million
Effective: 2022-10-21

Exact text from the filing

On October 21, 2022 (the “Effective Date”), Taysha Gene Therapies, Inc. (the “Company”) entered into an Option Agreement (the “Option Agreement”) with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) (“Astellas”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Taysha Gene Therapies, Inc. entered into Securities Purchase Agreement with Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas") valued at approximately $30.0 million (effective 2022-10-21).

Action: entry
Agreement: equity purchase
Counterparty: Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) ("Astellas")
Value: approximately $30.0 million
Effective: 2022-10-21

Exact text from the filing

On October 21, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Astellas, pursuant to which the Company agreed to issue and sell to Astellas in a private placement (the “Private Placement”) an aggregate of 7,266,342 shares

View on SEC.gov

Browse all material agreements →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-273298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.